-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 14-16, 2021, the 5th Hangzhou Xianghu International Breast Cancer Summit (HXIBCS) and the 6th Hangzhou Xianghu Breast Cancer Forum for Young and Middle-aged People were successfully held in Hangzhou.
In the special session of the Zhejiang Medical Association Cancer Chemotherapy and Biological Therapy Annual Conference, Professor Shan Jianzhen from the First Affiliated Hospital of Zhejiang University School of Medicine shared the progress of medical treatment of esophageal cancer.
After the meeting, Yimaitong invited Professor Shan Jianzhen to conduct an exclusive interview to talk about the progress and exploration direction of immunotherapy for esophageal cancer.
Professor Shan Jianzhen, Director, Department of Oncology (4), The First Affiliated Hospital of Zhejiang University School of Medicine, Member of the Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Special Committee Member, CSCO Immunotherapy Special Committee Member, CSCO Patient Education Special Committee Member, China Medical Promotion Association Member of the Thoracic Oncology Committee, Visiting Scholar, University of California, Los Angeles, U.
S.
A.
, Member of the Standing Committee of the Zhejiang Anti-Cancer Association's Tumor Targeting Committee, Member of the Standing Committee of the Zhejiang Anti-Cancer Association Precision Diagnosis and Treatment Committee, Zhejiang Association of Mathematical and Physical Medicine, and Standing Committee of the Thoracic Tumor Integration Committee, Zhejiang Member of the Provincial Anti-Cancer Association’s Etiology Committee, the immunotherapy is advancing from advanced esophageal cancer to neoadjuvant and postoperative adjuvant therapy.
Professor Shan Jianzhen: As we all know, esophageal cancer is a high-incidence malignant tumor in China and the world, and patients with advanced esophageal cancer The median survival time is no more than 1 year.
With the breakthrough of immunotherapy in various fields such as melanoma and lung cancer, the clinical exploration of immunotherapy for patients with advanced esophageal cancer has also begun.
After immunotherapy entered the field of esophageal cancer, it has brought about earth-shaking changes, gradually moving from the back line to the front line, with neoadjuvant and postoperative adjuvant therapy advancing.
For locally advanced esophageal cancer, the CheckMate 577 study published in the New England Journal of Medicine recently explored the adjuvant therapeutic value of immunotherapy after complete surgical resection of stage II/III esophageal cancer/gastroesophageal junction cancer, which proved immune Adjuvant therapy can bring significant clinical improvement in disease-free survival for patients with resectable esophageal cancer/gastroesophageal junction cancer, and related clinical research on neoadjuvant immunotherapy for esophageal cancer is also rapidly advancing.
Esophageal cancer immunotherapy allows patients to live longer and better lives Professor Shan Jianzhen: Immunotherapy, as a new treatment method, brings new hope for the treatment of esophageal cancer and will definitely rewrite the future treatment of esophageal cancer Pattern.
Since most of the esophageal cancer patients in my country are in the middle and advanced stages, and inoperable patients account for a large proportion, in the future, we will continue to explore whether immunotherapy can give inoperable esophageal cancer patients the opportunity to be surgically removed, allowing more advanced patients to live longer.
In addition, in the field of adjuvant therapy, how to reduce the risk of postoperative recurrence of patients, screen more precise immune benefit populations, and explore efficient immunization combinations require us to further carry out more clinical research.
In the special session of the Zhejiang Medical Association Cancer Chemotherapy and Biological Therapy Annual Conference, Professor Shan Jianzhen from the First Affiliated Hospital of Zhejiang University School of Medicine shared the progress of medical treatment of esophageal cancer.
After the meeting, Yimaitong invited Professor Shan Jianzhen to conduct an exclusive interview to talk about the progress and exploration direction of immunotherapy for esophageal cancer.
Professor Shan Jianzhen, Director, Department of Oncology (4), The First Affiliated Hospital of Zhejiang University School of Medicine, Member of the Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Special Committee Member, CSCO Immunotherapy Special Committee Member, CSCO Patient Education Special Committee Member, China Medical Promotion Association Member of the Thoracic Oncology Committee, Visiting Scholar, University of California, Los Angeles, U.
S.
A.
, Member of the Standing Committee of the Zhejiang Anti-Cancer Association's Tumor Targeting Committee, Member of the Standing Committee of the Zhejiang Anti-Cancer Association Precision Diagnosis and Treatment Committee, Zhejiang Association of Mathematical and Physical Medicine, and Standing Committee of the Thoracic Tumor Integration Committee, Zhejiang Member of the Provincial Anti-Cancer Association’s Etiology Committee, the immunotherapy is advancing from advanced esophageal cancer to neoadjuvant and postoperative adjuvant therapy.
Professor Shan Jianzhen: As we all know, esophageal cancer is a high-incidence malignant tumor in China and the world, and patients with advanced esophageal cancer The median survival time is no more than 1 year.
With the breakthrough of immunotherapy in various fields such as melanoma and lung cancer, the clinical exploration of immunotherapy for patients with advanced esophageal cancer has also begun.
After immunotherapy entered the field of esophageal cancer, it has brought about earth-shaking changes, gradually moving from the back line to the front line, with neoadjuvant and postoperative adjuvant therapy advancing.
For locally advanced esophageal cancer, the CheckMate 577 study published in the New England Journal of Medicine recently explored the adjuvant therapeutic value of immunotherapy after complete surgical resection of stage II/III esophageal cancer/gastroesophageal junction cancer, which proved immune Adjuvant therapy can bring significant clinical improvement in disease-free survival for patients with resectable esophageal cancer/gastroesophageal junction cancer, and related clinical research on neoadjuvant immunotherapy for esophageal cancer is also rapidly advancing.
Esophageal cancer immunotherapy allows patients to live longer and better lives Professor Shan Jianzhen: Immunotherapy, as a new treatment method, brings new hope for the treatment of esophageal cancer and will definitely rewrite the future treatment of esophageal cancer Pattern.
Since most of the esophageal cancer patients in my country are in the middle and advanced stages, and inoperable patients account for a large proportion, in the future, we will continue to explore whether immunotherapy can give inoperable esophageal cancer patients the opportunity to be surgically removed, allowing more advanced patients to live longer.
In addition, in the field of adjuvant therapy, how to reduce the risk of postoperative recurrence of patients, screen more precise immune benefit populations, and explore efficient immunization combinations require us to further carry out more clinical research.
